Skip to search formSkip to main contentSkip to account menu

Regional Differences in the Prescription of Biologics for Psoriasis in Sweden: A Register-Based Study of 4168 Patients

Geographical differences in biologics prescription persist after adjusting for patient characteristics and disease severity, and the Swedish example calls for further improvements in delivering equitable psoriasis care.
Springer (opens in a new tab)

Dynamics of socioeconomic-related health inequalities in Australia

The study indicates that there has been a positive increase in the concentration index for both males and females in Australia between 2001 and 2005, and concludes that estimates from Australia are akin to estimates from Scotland and England & Wales.

Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy

Both comorbidities and life style factors were associated with persisting moderate-to-severe psoriasis, despite ongoing systemic treatment, and the considerably lower generic quality of life in patients demonstrates an unmet need.
Taylor & Francis (opens in a new tab)

EXPLORING PATENT ACTIVITY AND ITS POTENTIAL ASSOCIATION WITH HEALTHCARE OUTCOMES: A CASE STUDY OF OSTOMY PRODUCTS IN SWEDEN

PA in the ostomy care industry was associated with reduced healthcare costs, but not necessarily with fewer skin complications, which suggests that there is a health economic benefit from products made by patent intensive companies which may differentiate them from generic comparators.
Cambridge Press (opens in a new tab)

Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice

Disease severity does not explain the decision to switch or not to switch to biologics for a disproportionate number of patients in Swedish clinical practice, but the type of healthcare provider cannot explain this variation.
Springer (opens in a new tab)

Regional Differences in the Prescription of Biologics for Psoriasis in Sweden: A Register-Based Study of 4168 Patients

Whether the opportunity for patients to receive biologics depends on where they receive care, and whether the likelihood of initiating a biologic and the region where patients received care was analyzed.
Springer (opens in a new tab)

The Dynamics of Income-Related Health Inequalities in Australia versus Great Britain

This study compares the evolution of income-related health inequality (IRHI) in Australia (2001–2006) and in Great Britain (1999–2004) by exploring patterns of morbidity- and mortality-related health…

Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice

There seems to be an uneven uptake of biologics in Swedish clinical practice, but the type of healthcare provider cannot explain this variation, and small or no difference in the probability of switch was observed between provider types.
Springer (opens in a new tab)

Excess costs of non-infectious comorbidities among people living with HIV – estimates from Denmark and Sweden

The high prevalence of comorbidities in the HIV-infected population is associated with substantial excess costs, and Focus on primary and secondary prophylactic interventions is warranted.
Taylor & Francis (opens in a new tab)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)
  NODES
Association 1
INTERN 1
Note 1